Home Markets Earnings Estimate Forecast on Tonix Pharmaceuticals Holding Corp.(TNXP)

Earnings Estimate Forecast on Tonix Pharmaceuticals Holding Corp.(TNXP)

3
SHARE

Tonix Pharmaceuticals Holding Corp.(TNXP): For the most recent quarter end, Tonix Pharmaceuticals Holding Corp. reported Annual Earnings of $-0.26. Based on the filings, last years Annual Earnings was, $-2.86. For the most recent quarter end, TNXP reported a surprise Earnings per Share of 23.53% . The consensus estimate for current quarter is $-0.16 and for the current fiscal year, the estimate is $-1.46. For the Next fiscal year, the estimate is $-0.4 based on the consensus. New York based Tonix Pharmaceuticals Holding Corp. Last reported the Quarter results on Dec 31, 2016 and the Next earnings date is scheduled to be released on Mar 03, 2017.

Tonix Pharmaceuticals Holding Corp. has received $-0.16 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 2 Financial Advisor in the Stock Trading Firms. Among 2 Analysts, Bottom line EPS Estimate for the current quarter is $-0.19 while the top line estimate is $-0.13 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at 77.46%. Tonix Pharmaceuticals Holding Corp. reported better than expected with a surprise EPS of 23.53% or $0.08 during its most recent quarterly earnings. The Actual EPS was $-0.26 compared to the Estimated EPS of $-0.34. According to the corporate earnings calendar, Tonix Pharmaceuticals Holding Corp. will release next earnings on Mar 03, 2017 with an estimated EPS consensus of $-0.16. Based on the consensus of stock financial advisors the stock has a price target of $1.2. Current year estimate on EPS consensus is $-1.46.

For Dividend Investing Stock Market Traders Tonix Pharmaceuticals Holding Corp. has a Dividend Yield of 0% with an Annual Dividend of $0.

Company has reported several Insider transactions to the SEC, on Nov 28, 2016, Ernest Mario (director) purchased 120,000 shares at 0.41 per share price.On Nov 22, 2016, Seth Lederman (CEO) purchased 98,000 shares at 0.43 per share price.On Oct 31, 2016, John B Rhodes (director) purchased 25,000 shares at 0.00 per share price.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) witnessed a decline in the market cap on Wednesday as its shares dropped 4.59% or 0.025 points. After the session commenced at $0.54, the stock reached the higher end at $0.54 while it hit a low of $0.5125. With the volume soaring to 796,783 shares, the last trade was called at $0.52. The company has a 52-week high of $3.77. The company has a market cap of $20 million and there are 39,200,000 shares in outstanding. The 52-week low of the share price is $0.352.

Tonix Pharmaceuticals Holding Corp. is a specialty pharmaceutical company focused on developing new pharmaceutical products for CNS conditions. The Company develops therapies for disorders that include fibromyalgia syndrome and post-traumatic stress disorder. Its lead product candidates include TNX-102, for the management of fibromyalgia syndrome and TNX-105 to treat symptoms of post-traumatic stress disorder. Tonix Pharmaceuticals Holding Corp. is headquartered in New York.

Tonix

LEAVE A REPLY

Please enter your comment!
Please enter your name here